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Abstract 
Purpose To evaluate clinical outcomes following sub-2-mm microincision cataract surgery 
(MICS) and intraocular lens (IOL) implantation.  
Setting Five EU clinical sites.  
Design Prospective, multicenter, open-label, single arm, non-randomized. 
Methods Preoperative assessment involved visual acuity (VA), intraocular pressure and 
biometry measurements. 1.4-mm wound-assisted or 1.8-mm MICS was performed. 
Follow-up visits were made 1 day, 1–2 weeks, 1–2 and 4–6 months after surgery. The 
incision size, corrected distance VA (CDVA), uncorrected distance VA, manifest refraction 
spherical equivalent (MRSE), refraction predictability/stability and IOL decentration were 
assessed. At 12-, 18-, and 24-month, long-term centration, posterior capsular 
opacification (PCO) and Nd:YAG capsulotomy rates were investigated. 
Results  A total of 103 eyes were implanted with the study IOL (INCISE, Bausch & Lomb), 
96 of which were included in visual outcome analysis. A mean 6-month CDVA of -  0.02 
logMAR (20/20 ?  1) was observed and 75 eyes (79.8%) and 93 eyes (98.3%)  achieved 
a visual acuity of at least 20/20 or 20/40. Mean MRSE was -  0.20 ± 0.60 D. Mean absolute 
predictive error was 0.44 ±  0.36 D, with 90.4% within 1.00 D of target. Mean total 
decentration was 0.35 ±  0.36 mm at 6 months and 0.32 ±  0.14 mm at 24 months (p[ 
0.05). 24-month evaluation of posterior capsular opacification score was 0.03 for the 
central area. A Nd:YAG rate of 3.4% was observed at 24 months. 
Conclusions The new MICS IOL provided excellent visual outcomes and was safe and 
effective for the sub- 2-mm procedure. The MICS IOL demonstrated longterm centration, 
stability and a low rate of PCO development. 
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Introduction 
Cataract surgery remains a curative intervention for restoring visual clarity and quality to 
cataract patients. However, it is a procedure that carries a risk of adverse effects, 
including surgically induced astigmatism, iris prolapse and decreased corneal optical 
quality due to higher-order aberrations (HOAs) [1]. Microincision cataract surgery (MICS), 
performed through an incision of less than 2 mm, has been developed as a method of 
minimizing corneal trauma and providing better postoperative outcomes than standard 
small incision phacoemulsification [2]. There are several forms of MICS available, and all 
have varying incision sizes. Biaxial microincision (BMICS) allows 1.5 mm or smaller 
incisions, while coaxial microincision (C-MICS), which is similar to the usual standard 
phacoemulsification technique, is used for incisions of 1.8 mm [3–6]. Published literature 
has shown that MICS offers improved control of surgically induced astigmatism and 
effective phacoemulsification time compared with standard small incision 
phacoemulsification [7]. Additionally, the control of surgically induced HOAs and better 
preservation of the optical quality of the cornea allow for further advantages of MICS, 
such as reduction in surgical trauma and less corneal biomechanical changes leading to 
an improvement in visual outcomes and patient satisfaction [8, 9]. 
However, current injection constraints (i.e., IOLs, inserters, and cartridges) make 
implantation of IOLs only possible via a wound-assisted technique. In this technique, the 
cartridge bevel does not enter the anterior chamber and it is currently the only injection 
technique that allows for the smallest incisions (i.e., \ 1.8 mm). A new microincision acrylic 
aspheric one-piece IOL (INCISE, Bausch & Lomb, USA) is optimized for implantation in 
the capsular bag through incisions of less than 2 mm. The lens has a lower water content 
(22%) than most MICS hydrophilic lenses on the market (25–26%). It is thought that this 
makes it stiffer and more resistant to tearing while passing through a 1.4-mm incision. It 
was designed to minimize PCO as evidenced by its sharper 360 degree posterior barrier 
edge with a 5 micron radius. The purpose of this study was to prospectively evaluate 
clinical outcomes following sub-2 mm MICS IOL implantation in cataract surgery using 
both conventional and wound-assisted implantation techniques. 
Methods 
Eligible subjects were scheduled to undergo microincision phacoemulsification cataract 
surgery and IOL implantation. Five clinical sites in the European Union (EU) were enrolled 
in this clinical investigation. The study eye was designated at the discretion of the 
investigator. All investigative sites had Ethics Committee (EC) approval before recruiting 
potential subjects. All patients provided a signed informed consent. 
This study was conducted in compliance with the protocol and in accordance with the 
Declaration of Helsinki, ISO 14155 (2011) Clinical Investigation of Medical Devices for 
Human Subjects, 42 USC 282(j), ICH GCPs, and applicable local regulations. The study 
included patients who met the following criteria: age 40 years or above with clinically 
significant cataract requiring phacoemulsification and IOL implantation with IOL power 
from 15 to 30 D. A clear cornea media and ability for the pupil to dilate to at least 6.5 mm 
in diameter (as measured with the pupil gauge) were also inclusion criteria in this study. 
Exclusion criteria included predisposing sightthreatening ocular conditions, evidence of 
iris or choroidal neovascularization, a history of corneal or  retinal surgery, glaucoma, 
optic atrophy, anterior segment pathology, associated ocular conditions which could 
affect the stability of the intraocular lens in the study eye (zonulolysis, defect zonules, 
evident zonular weakness or dehiscence), those taking medications known to potentially 
complicate cataract surgery (e.g., a 1a-selective alpha blocker), as well as patients with 
preoperative corneal astigmatism [ 1.5 D and cataract severity grade 4 (Table 1 ). 
 
Preoperative assessment 
All patients had a complete preoperative ophthalmic examination including corrected 
distance visual acuity (CDVA), subjective refraction, biomicroscopy of the anterior and 
posterior eye segments, dilated pupil size diameter and IOP measurement. Optical 
biometry (IOL-Master, Jena, Carl Zeiss Meditec AG) was performed in 96.1% of cases. 
Immersion ultrasound and the contact ultrasound technique were used in 1 and 3 eyes. 
The SRK/T formula was used for calculating the IOL power and target refraction was 
aimed as close to emmetropia as possible. Cataracts were classified preoperatively using 
the 4 grading scales of lens opacities classification system (LOCS) III: nuclear 
opalescence (NO), nuclear color (NC), cortical cataract (C), and posterior subcapsular 
cataract (P). 
Study intraocular lens 
The microincision IOL (INCISE, Bausch & Lomb, USA) is a one-piece foldable hydrophilic 
acrylic aspheric lens that must be implanted in the capsular bag (Fig. 1 a, b). The lens 
material is a copolymer of HEMA, and MMA, with water content lower than that of other 
hydrophilic acrylic IOLS (22%). It has an ultraviolet (UV) absorber allowing a 10% UV 
cutoff C  370 nm for a lens of 20 D. The lens has aberration free aspheric optics on both 
the anterior and posterior surface and four angulated haptics. It also has two orientation 
features (on a topright– bottom-left axis) to aid in appropriate loading of the lens. The lens 
has a 5 l m radius 360_  posterior square barrier edge (Fig. 1 c). 
 
 
Surgical technique  
All cataract surgeries were performed using the Stellaris Vision Enhancement System 
(Bausch ? Lomb, USA), and the study lens was implanted through a clear corneal incision, 
using the VISCOJECT 1.5 single-use injector (Medicel, Switzerland). All eyes either 
underwent B-MICS or C-MICS. For B-MICS, the lens was implanted using the wound-
assisted technique (tip of the cartridge at the edge of the incision) through an approximate 
1.4-mm incision using either the 1.4-mm angled (Beaver- Visitec, UK) or the 1.5–1.7-mm 
angled (Storz, Germany) calibrated knives. For C-MICS, the study lens was implanted 
with the tip of the cartridge entering in the anterior chamber through an approximate 1.8-
mm incision using 1.6–1.8-mm angled calibrated knives (Storz, Germany). The incision 
size chosen for each patient was determined by the current surgical technique of the 
operating surgeon: biaxial (1.4 mm) and coaxial (1.8 mm) technique. Incision size was 
measured using gauges from 1.0 to 2.5-mm by 0.1-mm step (ASICO Gauges—Ref AE- 
1574T) before phacoemulsification before and after IOL insertion. Before and after 
INCISE IOL injection the anterior chamber was filled with ophthalmic viscosurgical device. 
Postoperative assessment 
Four comprehensive postoperative follow-up visits at 1 day, 1–2 weeks, 1–2 months, and 
4–6 months following surgery were performed in all participants. During these visits, 
corrected (CDVA; primary study endpoint) and uncorrected distance visual acuity (UDVA) 
were assessed using logMAR visual acuity scales. Manifest refraction spherical 
equivalent (MRSE), predictability of refraction (assessed as deviation from targeted 
refraction), and stability of refraction [refraction results at month 6 vs. month 2 (defined 
using the ANSI criteria)] [10 ] were also assessed. Horizontal and vertical lens 
decentration relative to the limbus (measured in millimeters from retroillumination 
photographs taken at postoperative visits 2–7), total decentration, posterior capsular 
opacification (EPCO) score (3 mm central and within the capsulorhexis area), Nd:YAG 
capsulotomy rate and ocular adverse events were recorded during follow-up visits. 
EPCO scores were determined by a single evaluator (P.B) who graded all photographs. 
These scores, along with Nd:YAG rates, were determined at further visits at 12, 18 and 
24 months postoperatively. 
Statistical analysis 
Following ISO 11979-7 the null hypothesis was that the proportion of eyes with CDVA of 
20/40 or better (p) was equal to or greater than the historical control proportion (p 0). The 
alternative hypothesis was that the proportion of eyes with CDVA of 20/40 or better was 
less than the historical control proportion. Regarding overall postoperative CDVA of 20/40 
or better, an exact binomial test with a nominal 0.050 one-sided significance level and 
80% power to detect the difference between the null hypothesis proportion, p 0 of 0.925 
and the Alternative proportion, p A, of 0.839 the required sample size was 90 subjects. 
Following assessment of normality, all continuous variables were summarized using 
descriptive statistics and categorical measures using counts and percentages. 
For the primary endpoint a one-sided exact binomial test was used with a Type 1 (alpha) 
error rate of 0.05 for comparison between the observed proportion of subjects with CDVA 
of 20/40 or greater and the historical control proportion. All other statistical analyses were 
performed using a two-sided hypothesis test at the 5% level of significance. No 
adjustments for Type I error were made for multiple comparisons. Unless otherwise 
noted, confidence intervals (CI) were two-sided with a 5% alpha risk (i.e., 95% confidence 
intervals). CIs for continuous variables are based on the t-distribution. CIs for 
dichotomous variables are exact binomial (Clopper–Pearson) confidence intervals.  
All summaries and analyses were prepared using SAS software (SAS Institute, Cary, 
N.C., version 9.2 or higher). 
Results 
Table 1 outlines the demographics of all subjects. A total of 111 patients and eyes (58 
right eyes) were enrolled in the study. Of these, 103 were successfully implanted with the 
study IOL and were labeled the Safety Set because their outcomes were used in safety 
analyses. These patients also comprised the Implanted set as they were all implanted 
with the IOL. An additional group called the Per-Protocol Set was also classified in the 
study and used for analysis of the visual outcomes achieved with the lens. This group 
consisted of 96 patients who were successfully implanted with the IOL and did not have 
any notable protocol deviations (defined as exclusion criteria arising after enrollment). Of 
the 103 patients implanted with the study IOL, 43 were implanted via B-MICS and 60 via 
C-MICS. The average age of the overall cohort (i.e., the Implanted Set) was 71.5 ±  7.6 
years (range 48–86 years) of which 61 (i.e., 59.2%) subjects were female and 42 (i.e., 
40.8%) subjects male. 83.5% (n  = 86 eyes) of the subjects enrolled presented with 
nuclear or cortico-nuclear cataract, evaluated as moderate or dense in 82.6% (n  = 85) of 
eyes. Target refraction was—0.20 ±  0.19 D. Looking specifically at the 96 eyes in the 
Per- Protocol Set, 39 eyes of these underwent IOL implantation using the wound-assisted 
technique (tip of the cartridge of the inserter at the edge of the incision) through an incision 
size of 1.4 ±  0.1 mm on average. Mean wound stretch was 0.2 ±  0.2 mm. In 57 eyes of 
the Per-Protocol Set, the study lens was implanted using the standard injection technique 
(tip of the cartridge of the inserter entering in the anterior chamber) through an incision 
size of 1.9 ±  0.1 mm on average. Mean wound stretch in this case was 0.1 ±  0.1 mm. 
Visual performance data 
The visual performance for the Per Protocol set, i.e., 96 eyes, for each visit is presented 
in Table 2 . There was a mean CDVA improvement of 3 lines at 1–2 weeks from 
preoperative visit, and then CDVA remained stable at 20/20 ?  1 Snellen on average. 
Furthermore, mean CDVA was -  0.02 logMAR (20/ 20 ?  1), and was 20/20 or better in 
79.8% of eyes and 20/40 or better for 93 eyes (98.3%) at 6 months postoperative. The 6-
month postoperative results showed a mean UDVA of ?  0.12 logMAR (20/25 Snellen), 
with 92.6% of eyes achieving 20/40 or better. There was an improvement of 5 lines on 
average from the preoperative visit. 
The 6-month mean MRSE was -  0.20 ±  0.60 diopters (D), mean absolute Predictive 
Error was 0.44 ±  0.36 D with 90.4% of the eyes within 1.00 D of the targeted refraction. 
Refractive stability, as indicated by the difference in refraction from the 4–6-month and 
1–2-month postoperative visits, was 0.02 ±  0.32 diopters with an absolute refractive 
change of 0.20 ±  0.25 D. 98.9% of the eyes had a change B  1.00 D in MRSE between 
V3 and V4 showing refractive stability was achieved 4–6 months after implantation. 
 
 
Safety parameters 
All eyes implanted with the MICS IOL (n  = 103 eyes) were included in the safety analysis.  
Lens decentration 
Mean total decentration is presented in Table 3 (relative to the limbus). As shown in Fig. 
2 , on a consistent cohort of 77 eyes (all implanted with no missing data at any visit), there 
were no statistically significant differences among visits (p  = 0.07). The MICS IOL was 
positioned on average at 0.30–0.35 mm from the superior nasal position, 12 months 
following implantation (Fig. 3). 
 
 
 
 
 
Evaluation of posterior capsular opacification (EPCO) score and Nd:YAG rate 
The data for all implanted eyes that did not receive a capsulotomy before the visit are 
presented in Table 4. Both 3 mm central and within the capsulerhexis areas EPCO scores 
were on average close to zero during the course of the 24 months following surgery, 
respectively (Fig. 4). EPCO score findings were 0.01, 0.03 and 0.07 within the 
capsulorhexis with no significant differences between study sites ( p[0.05). Nd:YAG rates 
were 0% until 12 months postoperative (11–13-month visit window), when thereafter three 
eyes among the 103 implanted eyes (2.9%) underwent a Nd:YAG capsulotomy for 
posterior capsule opacification visual disturbance. Nd:YAG rates were 3.4% (3/88 eyes 
were followed up to 24 months) (Table 5). 
 
 
 
 
 Adverse events 
One patient experienced low visual acuity and reported glare. Laser capsulotomy was 
performed before 2 months to treat a primary posterior capsular plaque that was observed 
intraoperatively and at the day 1 postoperative visit. Two cases of cystoid macular edema 
(CME), one still persistent at 4–6 months postoperatively, were recorded. No other 
adverse events, i.e., posterior capsular tear, IOL malposition, iris damage, Descemet’s 
membrane detachment, or retinal detachment were noted. No relationship between the 
surgical technique and occurrence of adverse events was noted. 
Discussion 
This prospective, multicenter study demonstrates that the used microincision IOL 
provides good visual and refractive outcomes. Specifically, the mean CDVA achieved 
with the IOL was -  0.02 logMAR (20/20), and 80% of eyes obtained a CDVA of 20/20 or 
better. Additionally, the CDVA was 20/40 or better for 93 eyes (98.3%) in the Per-Protocol 
Set and for all eyes (100%) in the Safety Set at the 6-month postoperative visit. This 
exceeds the historical control ISOGrid [11 ] of 92.5 and 96.7%, respectively, for CDVA of 
20/40 or better. The visual performance data of this study also show that the mean MRSE 
was -  0.20 ±  0.60 D, while mean absolute predictive error was 0.44 ±  0.36 D within 1.00 
D of the targeted refraction for 90.4% of eyes. 
These outcomes are consistent with the recommendations based on the EUREQUO 
registry [11 ] and the UK NHS benchmark data [12 ] with 87.0 and 85.0% of eyes within 
1.00 D, respectively. Of course, better outcomes may be achieved with greater 
experience and personalizing the A constant for this MICS IOL. A constant optimization 
performed by Dr Wolfgang Haigis reported that the A constant should be slightly 
decreased from 119.1 to 118.9 [13]. Applying this optimized A constant to the study data 
set would have slightly improved the refraction predictability with 92.0% of cases within 
1.00 D of expected refraction. It is understood that postcataract surgery, MICS provides 
the opportunity to achieve an advanced refractive result with less perioperative injury. 
This is thought to be because, unlike with coaxial cataract surgery technique, MICS does 
not induce further incision healing process, inflammation of the anterior chamber, corneal 
endothelial loss, or corneal edema [14 , 15 ]. However, due to the very high technical and 
optical requirements needed to meet the sub-2-mm incision demand, there are only very 
few MICS IOLs commercially available. The refractive outcomes achieved in the current 
study suggest that the used microincision IOL meets these technical requirements. A 
further technical requirement of a MICS IOL is to exhibit long-term stability in the bag to 
ensure consistently high visual clarity, quality and patient satisfaction long after surgery. 
The microincision IOL demonstrated a predictable and stable centration with a mean total 
decentration of 0.32 ± 0.14 mm in a superior nasal direction 24 months following 
implantation. These results are consistent with those previously reported with 
conventional one or three-piece IOLs, falling within a range of 0.20–0.60 mm[16 –21 ]. 
The location of the IOL was assessed in relation to the geographical center of the cornea 
rather than the visual axis; also located nasally. Despite advances in IOL designs and 
modern surgical techniques, posterior capsule opacification (PCO) remains the most 
common complication after cataract surgery. Experimental works by Nishi et al. [22 –24 ] 
on physiopathology and mechanisms of PCO have shown that the most important feature 
of midterm PCO prevention is the square edge design. This was clinically confirmed by 
Buehl et al. [25 ] in a metaanalysis which followed prospective controlled randomized 
trials in a 12-month follow-up period. A Cochrane review by Findl et al. [26 ] analyzed the 
roles that IOL material, lens geometry, pharmacology therapy, and surgical technique 
have on PCO development. PCO score was found to be significantly lower with sharp-
edge design IOLS, whereas there was no evidence of the optic material having an 
influence. However, limited long-term follow-up and large variation in the PCO score 
systems led to difficulties pooling the data. Using scanning electron microscopy (SEM), 
several experimental studies have evaluated the square edge profile of a variety of IOLs 
[27 –29 ]. Despite the different quantification methods used by these in vitro studies (i.e., 
deviation from a perfect square [27 , 28 ] or mean radius curvature [29 ]) their conclusions 
were comparable: hydrophilic acrylic IOLs appear to have relatively rounder edges than 
silicone and hydrophobic IOLs. But these results suggest that variation in PCO incidence 
is more reflective of differences in manufacturing processes rather than the IOL material. 
For example, during the polishing process, hydrophilic lenses may experience abrasion 
of the square edges. Thus, the polishing process adopted by the manufacturer can 
determine the level of the edge sharpness. Hydrophobic lenses in comparison, however, 
are usually molded with no polishing step. 
Owing to the specific manufacturing process and its 5 l m radius 360_  sharp posterior 
optic edge, the microincision IOL used in this study demonstrated a low score of PCO 
development with mean 3 mm central and within the capsulorhexis area EPCO scores of 
0.03 ±  0.09 and 0.07 ±  0.17, respectively, 24 months after surgery. To quantify PCO, 
different methods of automated analysis and digital imaging are available, but the most 
common measurement in clinical trials remains the Nd:YAG capsulotomy rate. The 24-
month incidence of Nd:YAG capsulotomy was 3.4%. This compares favorably with the 
results obtained with other hydrophilic lenses with incidence rates reported from 4.2 to 
50% [30 –34 ], and especially other microincision lenses, with an incidence reported from 
8.0 to 64.5% [35 –39 ]. All reported adverse events and complications during the 4–6-
month follow-up were expected events anticipated after any cataract surgery with IOL 
implantation and not unique or specifically associated with the IOL. A key limitation of the 
current study is the absence of investigation of patient satisfaction or corneal higher-order 
aberrations. However, as there are previous reports on studies investigating aberrations 
with MICS [8 , 40 , 41 ], the current study design instead allows for an effective review of 
the visual performance and long-term safety profiles of a MICS IOL. Study size is another 
limitation of the current study. While approximately 100 eyes give good indication of the 
outcomes achievable with the INCISE IOL, further larger-scale studies will be valuable in 
corroborating and building on the findings seen in the current study. It is also worth noting 
that the follow-up period of 24 months used in the current study is an additional limitation. 
Literature shows that PCO can develop long after cataract surgery. As such, while the 
current study provides indication of the short- and mediumterm PCO rates associated 
with the INCISE IOL, studies with longer follow-up in the range of 10 years are required 
to determine whether these rates remain the same long term. Finally, as no toric version 
of the IOL was available at the time of the study, subjects with an astigmatism[ 1.5 D were 
excluded. Both this population as well as those with a cataract severity grade 4 should be 
evaluated in a future study. 
 
Conclusion 
The results of this study show, for the first time, the visual performance and long-term 
safety data for the MICS INCISE IOL, demonstrating good visual acuity and excellent lens 
stability alongside low PCO rates and adverse events.  
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